Proactive research analyst says Tiziana Life Sciences "moving forward quite nicely"

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

--News Direct--

Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a 2023 Clinical Outlook for clinical stage biotechnology company Tiziana Life Sciences Ltd (NASDAQ: TLSA). He gives his take on what the market can expect from the business this year, saying that it is now "moving forward quite nicely."

Contact Details

Proactive UK Ltd

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/proactive-research-analyst-says-tiziana-life-sciences-moving-forward-quite-nicely-546792176

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  272.68
+1.51 (0.56%)
AAPL  293.32
+5.88 (2.05%)
AMD  455.19
+46.73 (11.44%)
BAC  51.31
-1.44 (-2.73%)
GOOG  397.05
+1.75 (0.44%)
META  609.63
-7.18 (-1.16%)
MSFT  415.12
-5.65 (-1.34%)
NVDA  215.20
+3.70 (1.75%)
ORCL  195.95
+1.36 (0.70%)
TSLA  428.35
+16.56 (4.02%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.